title: Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.
abstract: We report an anaphylactic reaction in a 45-year-old gentleman with an 8-year history of extensively treated, relapsing follicular lymphoma who was receiving a second treatment with ibritumomab tiuxetan. Within seconds of receiving Y-90 ibritumomab, he developed chest tightness, shallow respirations, hypotension, and incontinence. After successful resuscitation, a human antimouse antibody (HAMA) level was found to be elevated, 618 ng/mL (reference 0-188 ng/mL).
authors.affiliation: UPMC Cancer Centers, UPMC Cancer Pavilion, Pittsburgh, Pennsylvania, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Jankowitz
authors.forename: Judith
authors.initials: J
authors.lastname: Joyce
authors.forename: Samuel A
authors.initials: SA
authors.lastname: Jacobs
mesh_terms: D000707:Anaphylaxis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008224:Lymphoma, Follicular / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D016499:Radioimmunotherapy / Q000379:methods; D015021:Yttrium Radioisotopes / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan